Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today...
The recent paper, published in Science Advances by the Computational Biology Laboratory at CICbioGUNE, member of the Basque Research & Technology Alliance BRTA and at Luxembourg Centre for Systems Bio...
A study by the URV’s Cheminformatics and Nutrition research group has shown that an anti-inflammatory drug for humans and another for animals inhibit a key enzyme in the replication and transcriptio...
The study, led by Cristina López-Rodríguez and Jose Aramburu shows that the transcription factor NFAT5, which induces multiple inflammatory mediators, represses type I interferons.